The Project: Proteomics Analysis of Chemoresistance in Bladder Cancer
Twenty-five percent of patients with bladder cancer are diagnosed with muscle invasive disease. These patients usually receive chemotherapy followed by surgery to remove the bladder. Up to 60% of tumors, however, do not respond to chemotherapy. This study aims to measure the abnormal biological pathways in bladder tumour tissue at the RNA and protein levels, and to identify the pathways responsible for resistance to chemotherapy. This approach will allow Dr. Black’s research team to identify mechanisms of resistance to chemotherapy and in the future test drugs that block the identified resistance pathways. If successful, this project will open the door to novel therapies to overcome chemo-resistance.
Dr. Black and Bladder Cancer Canada thank our generous donors and supporters for making this important research project possible.
In 2018, Bladder Cancer Canada received eleven high quality applications for research funding from recognized institutions across Canada; unfortunately, we could fund only one. Every year, we receive many more applications for research funding than we can support financially. But with your help, we can change that: join Bladder Cancer Canada in its efforts to fund new and innovative projects to fight bladder cancer. Contact us to discuss how your financial support can affect the future of bladder cancer research and innovation.
Pictured (L-R) are: Gregg Morin, PhD (Head of Proteomics, BC Cancer Genome Sciences Centre), Peter Black, MD FRCSC (Professor, University of British Columbia), Josa Batista da Costa, MD (post-doc), Kenichiro Ikeda, MD PhD (post-doc)